Urinary Tract Physiological Conditions Promote Ciprofloxacin Resistance in Low-Level-Quinolone-Resistant Escherichia coli

Antimicrobial Agents and Chemotherapy
Guillermo Martín-GutiérrezJesús Blázquez

Abstract

Escherichia coli isolates carrying chromosomally encoded low-level-quinolone-resistant (LLQR) determinants are frequently found in urinary tract infections (UTIs). LLQR mutations are considered the first step in the evolutionary pathway producing high-level fluoroquinolone resistance. Therefore, their evolution and dissemination might influence the outcome of fluoroquinolone treatments of UTI. Previous studies support the notion that low urine pH decreases susceptibility to ciprofloxacin (CIP) in E. coli However, the effect of the urinary tract physiological parameters on the activity of ciprofloxacin against LLQR E. coli strains has received little attention. We have studied the activity of ciprofloxacin under physiological urinary tract conditions against a set of well-characterized isogenic E. coli derivatives carrying the most prevalent chromosomal mutations (ΔmarR, gyrA-S83L, gyrA-D87N, and parC-S80R and some combinations). The results presented here demonstrate that all the LLQR strains studied became resistant to ciprofloxacin (according to CLSI guidelines) under physiological conditions whereas the control strain lacking LLQR mutations did not. Moreover, the survival of some LLQR E. coli variants increased up to 100-fol...Continue Reading

References

Apr 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C S LewinJ T Smith
May 1, 1991·Mutation Research·E Gocke
Jan 1, 1990·Urologia Internationalis·V M BilobrovV I Bessarabov
Jul 1, 1995·Journal of the American Dietetic Association·T Remer, F Manz
Jan 1, 1997·International Urology and Nephrology·X GiannakopoulosK Charalambopoulos
Feb 24, 2000·Physiological and Biochemical Zoology : PBZ·M R FrazierS T Behmer
Apr 11, 2001·Emerging Infectious Diseases·D C Hooper
Oct 31, 2002·Clinical Pharmacokinetics·M Dolores Sánchez NavarroAmparo Sánchez-Navarro
Sep 25, 2003·Antimicrobial Agents and Chemotherapy·Patricia Komp LindgrenDiarmaid Hughes
Feb 27, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ebbing LautenbachNeil O Fishman
Apr 17, 2004·Kidney International·Naim M MaaloufCharles Y C Pak
Apr 26, 2005·International Journal of Antimicrobial Agents·Katie L HopkinsE John Threlfall
Apr 7, 2006·Journal of the American Society of Nephrology : JASN·Mary Ann CameronKhashayar Sakhaee
Feb 13, 2007·International Journal of Antimicrobial Agents·Loren G MillerAngela W Tang
Feb 12, 2008·Journal of Medicinal Chemistry·Rosemarie O'Shea, Heinz E Moser
Aug 21, 2008·Journal of Analytical Toxicology·Stephanie J MarinGwendolyn A McMillin
Jun 30, 2010·The Journal of Clinical Psychiatry·Giovanni A FavaSilvana Grandi
Dec 3, 2010·The Journal of Antimicrobial Chemotherapy·Willize E van der StarreJaap T van Dissel
Feb 4, 2011·Research in Microbiology·Zeynep Erdogan-YildirimMarkus Zeitlinger
Feb 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kalpana GuptaEuropean Society for Microbiology and Infectious Diseases
May 15, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Gergely VölgyiKin Y Tam
Aug 2, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Csaba P Kovesdy
Mar 8, 2013·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·R ParasuramanAST Infectious Diseases Community of Practice
Feb 11, 2014·The Journal of Antimicrobial Chemotherapy·Joep van den Broek d'ObrenanAlike W van der Velden
Aug 21, 2014·The Journal of Antimicrobial Chemotherapy·Jesús MachucaJosé-Manuel Rodríguez-Martínez
Oct 9, 2014·The New England Journal of Medicine·Kenrick BerendRijk O B Gans
Jul 21, 2015·Annals of the New York Academy of Sciences·David C Hooper, George A Jacoby
Sep 19, 2015·Journal of Visualized Experiments : JoVE·Laura M KoethSandra McCurdy

Related Concepts

Bacteriocidal Agents
Ciprinol
Alkalescens-Dispar Group
Escherichia Coli Infections
Hydrogen-Ion Concentration
Fungus Drug Sensitivity Tests
Urinary Tract Infection
Quinolones
Fluoroquinolones
Antibiotic Resistance, Bacterial

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.